Skip to content

Agios Pharmaceuticals AGIO Convertible Preferred Stock Issued Shares

Convertible Preferred Stock Issued Shares at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
0
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
0
Incyte logo
IncyteINCY
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.12B+18.1%
Enterprise value$2.04B+15.2%
P/S32.1×-16.4×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%
Debt / equity0.0×
Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesIssued.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's convertible preferred stock issued shares.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's convertible preferred stock issued shares?
Agios Pharmaceuticals (AGIO) reported convertible preferred stock issued shares of 0 in Q1 2026.
What does convertible preferred stock issued shares mean?
Number of convertible preferred shares that have been issued, whether held by investors or in treasury.